Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0B65S3
Fri, 31.03.2023
PAION AG
PAION AG implements resolved capital reduction
Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin [ … ]
Fri, 31.03.2023
PAION AG
PAION AG implements resolved capital reduction
Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin [ … ]
Thu, 30.03.2023
PAION AG
PAION AG reports on fiscal year 2022
Combined revenues of EUR 33.2 million
Cash and cash equivalents of EUR 10.6 million as of 31 December 2022
Positive EBITDA of EUR 1.5 million
Capital reduction carried out in the first quarter of 2023
Initiatives to expand commercial distribution continued, including the successful expansion of partner ne [ … ]
Thu, 30.03.2023
PAION AG
PAION AG reports on fiscal year 2022
Combined revenues of EUR 33.2 million
Cash and cash equivalents of EUR 10.6 million as of 31 December 2022
Positive EBITDA of EUR 1.5 million
Capital reduction carried out in the first quarter of 2023
Initiatives to expand commercial distribution continued, including the successful expansion of partner ne [ … ]
Thu, 16.03.2023
PAION AG
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels
PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II
Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65 [ … ]
Thu, 16.03.2023
PAION AG
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels
PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II
Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65 [ … ]
Wed, 25.01.2023
PAION AG
PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing
Aachen (Germany), 25 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesi [ … ]
Thu, 19.01.2023
PAION AG
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL
Aachen (Germany), 19 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensiv [ … ]
Fri, 16.12.2022
PAION AG
PAION AG issues statement on planned capital measure
Aachen (Germany), 16 December 2022 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anaesthesia and intensive care, announced on Wednesday, 14 December 2022, [ … ]
Fri, 16.12.2022
PAION AG
PAION AG issues statement on planned capital measure
Aachen (Germany), 16 December 2022 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anaesthesia and intensive care, announced on Wednesday, 14 December 2022, [ … ]